Kymera Therapeutics KYMR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.48M+31.3% | $39.21M-10.3% | $43.73M-2.2% | $44.71M-24.1% | $58.89M+25.1% | ||
| $334.48M+5.7% | $316.57M+3.9% | $304.55M+4.7% | $290.87M+7.1% | $271.68M+13.1% | ||
| $72.27M+6.0% | $68.19M+0.9% | $67.58M+2.9% | $65.7M+0.4% | $65.43M+3.0% | ||
| $410.6M+5.7% | $388.61M+3.4% | $375.99M+5.4% | $356.57M+5.8% | $337.12M+9.2% | ||
| -$359.13M-2.8% | -$349.4M-5.2% | -$332.26M-6.5% | -$311.86M-12.1% | -$278.23M-6.3% | ||
| -697.7%+193pp | -891.1%-131pp | -759.7%-62.2pp | -697.5%-225pp | -472.5%+83.3pp | ||
| $44.12M+16.0% | $38.05M+2.5% | $37.14M+1.9% | $36.43M-2.5% | $37.35M-1.1% | ||
| -$315M-1.2% | -$311.35M-5.5% | -$295.12M-7.1% | -$275.43M-14.3% | -$240.88M-7.6% | ||
| -612%+182pp | -794.1%-119pp | -674.8%-58.8pp | -616%-207pp | -409.1%+66.5pp | ||
| -$3.58+3.0% | -$3.69-2.5% | -$3.60-3.4% | -$3.48-11.9% | -$3.11-4.4% | ||
| -$350.84M-2.9% | -$341.09M-5.3% | -$323.99M-6.7% | -$303.76M-12.4% | -$270.27M-6.3% | ||
| -681.6%+188pp | -869.9%-129pp | -740.8%-61.4pp | -679.4%-220pp | -459%+81.2pp | ||
| -$359.13M-2.8% | -$349.4M-5.2% | -$332.26M-6.5% | -$311.86M-12.1% | -$278.23M-6.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kymera Therapeutics's revenue?
- Kymera Therapeutics (KYMR) generated $51.5M in revenue over the trailing twelve months, down 12.6% year over year.
- Is Kymera Therapeutics profitable?
- Kymera Therapeutics is not currently profitable: it reported a net loss of $315.0M over the trailing twelve months, a -612.0% net margin.
- What is Kymera Therapeutics's earnings per share?
- Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.58.
- Where does Kymera Therapeutics's income statement data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
